Production, quality control and characterization of an inactivated hepatitis A vaccine

Peetermans, J

doi:10.1016/0264-410x(92)90557-z

Cited by 76 publications

(25 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a formol-inactivated whole-virion vaccine adsorbed on aluminum hydroxide with 2-phenoxyethanol as a preservative. The detailed composition of this vaccine, its manufacture, quality control and clinical development have been described elsewhere [41,42]. The HM175 strain of HAV used for the manufacture of Havrix gives high yields in cell culture.…”

Section: Prevention Of Hepatitis a By Vaccinationmentioning

confidence: 99%

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

André

Damme

Safary

et al. 2002

Expert Review of Vaccines

View full text Add to dashboard Cite

There is 10 years of marketing experience with the hepatitis A vaccine Havrix. It is highly immunogenic, provides lasting protection in healthy individuals and generates protective levels of antibodies in patients with chronic liver disease or impaired immunity. Postmarketing surveillance data have confirmed the outstanding safety profile of the vaccine. The timing of the booster dose is not critical to effectiveness, which has advantages for the protection of travelers to regions of high endemicity. The vaccine is effective in curbing outbreaks of hepatitis A and also when administered postexposure, due to rapid seroconversion and the long incubation period of the disease. In intermediate endemic regions, an epidemiological shift in hepatitis A infection has driven the development of universal preventive strategies to be added to the targeting of at-risk groups. Existing official recommendations and future directions for vaccine use are reviewed.

show abstract

Section: Prevention Of Hepatitis a By Vaccinationmentioning

confidence: 99%

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

André

Damme

Safary

et al. 2002

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…The aluminum adjuvanted vaccines should not be frozen. Both the Merck and the GSK products retain potency for two years at 2-8º C (14,106,113). ADTs performed on GSK vaccine lots at release and after storage for 15 months in a refrigerator indicate no loss of immunogenicity at 37°C for up to three weeks (106).…”

Section: Hepatitis a Vaccinementioning

confidence: 99%

“…Both the Merck and the GSK products retain potency for two years at 2-8º C (14,106,113). ADTs performed on GSK vaccine lots at release and after storage for 15 months in a refrigerator indicate no loss of immunogenicity at 37°C for up to three weeks (106). The reactogenicity and immunogenicity of Havrix (the GSK product) was stable after 37ºC for one week (25,113,185,186).…”

Section: Hepatitis a Vaccinementioning

confidence: 99%

Effect of Freezing on Oxytocin Ampules

2013

View full text Add to dashboard Cite

“…This benefit occurs for two reasons. First, a number of nongenetic factors may influence antibody levels (and cellular immune responses) following vaccination, including the presence of maternal antibodies [48], race [49], differences in vaccine storage, handling and administration [50,51], and concurrent illness at the time of vaccine administration [52–54]. However, twins who are raised together are highly likely to share these and other factors (such as exposure to viral diseases) that may influence measures of vaccine immunity.…”

Section: Specific Examples Of Prophylactic Vaccinesmentioning

confidence: 99%

Application Of Pharmacogenomics To Vaccines

2009

View full text Add to dashboard Cite

The field of pharmacogenomics and pharmacogenetics provides a promising science base for vaccine research and development. A broad range of phenotype/genotype data combined with highthroughput genetic sequencing and bioinformatics are increasingly being integrated into this emerging field of vaccinomics. This paper discusses the hypothesis of the 'immune response gene network' and genetic (and bioinformatic) strategies to study associations between immune response gene polymorphisms and variations in humoral and cellular immune responses to prophylactic viral vaccines, such as measles-mumps-rubella, influenza, HIV, hepatitis B and smallpox. Immunogenetic studies reveal promising new vaccine targets by providing a better understanding of the mechanisms by which gene polymorphisms may influence innate and adaptive immune responses to vaccines, including vaccine failure and vaccine-associated adverse events. Additional benefits from vaccinomic studies include the development of personalized vaccines, the development of novel vaccines and the development of novel vaccine adjuvants.

show abstract

Production, quality control and characterization of an inactivated hepatitis A vaccine

Cited by 76 publications

References 3 publications

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

Inactivated hepatitis A vaccine: immunogenicity, efficacy, safety and review of official recommendations for use

Effect of Freezing on Oxytocin Ampules

Application Of Pharmacogenomics To Vaccines

Contact Info

Product

Resources

About